INCY

INCY

USD

Incyte Corp. Common Stock

$102.920+1.560 (1.539%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$101.360

High

$103.860

Low

$100.020

Volume

2.74M

Company Fundamentals

Market Cap

20.2B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

2.00M

Exchange

NMS

Currency

USD

52-Week Range

Low $53.56Current $102.920High $103.86

Related News

Analyst Upgrades

Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $102

Piper Sandler analyst Allison Bratzel maintains Incyte with a Overweight and raises the price target from $82 to $102.

View more
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $102
GlobeNewswire

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with

View more
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Analyst Upgrades

Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target

Guggenheim analyst Michael Schmidt upgrades Incyte from Neutral to Buy and announces $125 price target.

View more
Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target
BusinessWire

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated

View more
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
BusinessWire

Incyte to Present at Upcoming Investor Conferences

Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00

View more
Incyte to Present at Upcoming Investor Conferences
GlobeNewswire

Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM

Analyst Upgrades

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $84

RBC Capital analyst Brian Abrahams maintains Incyte with a Sector Perform and raises the price target from $81 to $84.